A multicenter, randomized, open-labelled, non-inferiority trial of sustained-release sarpogrelate versus clopidogrel after femoropopliteal artery intervention

[1]  Manesh R. Patel,et al.  Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD , 2021, Circulation.

[2]  C. Mena-Hurtado,et al.  Real-World Antithrombotic Treatment Variability in Patients Undergoing Peripheral Vascular Intervention: Insights from the VQI Registry. , 2021, American heart journal.

[3]  Sonia S Anand,et al.  Total Ischemic Event Reduction with Rivaroxaban after Peripheral Arterial Revascularization in the VOYAGER PAD Trial. , 2021, Journal of the American College of Cardiology.

[4]  Manesh R. Patel,et al.  Rivaroxaban in Peripheral Artery Disease after Revascularization. , 2020, The New England journal of medicine.

[5]  Tracy Y. Wang,et al.  Long-Term Outcomes and Associations With Major Adverse Limb Events After Peripheral Artery Revascularization. , 2020, Journal of the American College of Cardiology.

[6]  L. Mazzolai,et al.  ESVM Guideline on peripheral arterial disease , 2019 .

[7]  J. Mao,et al.  Local infiltration with cocktail analgesics during 2 level lumbar spinal fusion surgery , 2019, Medicine.

[8]  P. Dall,et al.  Living a burdensome and demanding life: A qualitative systematic review of the patients experiences of peripheral arterial disease , 2018, PloS one.

[9]  A Ross Naylor,et al.  2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed b , 2018, European heart journal.

[10]  P. Thompson,et al.  Review of aspirin and clopidogrel resistance in peripheral arterial disease , 2017, Journal of vascular surgery.

[11]  S. Min,et al.  SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial , 2017, Trials.

[12]  S. Johansson,et al.  Cardiovascular outcomes in patients with peripheral arterial disease as an initial or subsequent manifestation of atherosclerotic disease: Results from a Swedish nationwide study , 2017, Journal of vascular surgery.

[13]  L. Fleisher,et al.  2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2017, Journal of the American College of Cardiology.

[14]  Freya J. I. Fowkes,et al.  Peripheral artery disease: epidemiology and global perspectives , 2017, Nature Reviews Cardiology.

[15]  T. Oh,et al.  Effect of sarpogrelate, a selective 5-HT2A receptor antagonist, on characteristics of coronary artery disease in patients with type 2 diabetes. , 2017, Atherosclerosis.

[16]  J. Coresh,et al.  Lower Extremity Peripheral Artery Disease and Quality of Life Among Older Individuals in the Community , 2017, Journal of the American Heart Association.

[17]  S. Johansson,et al.  Long-Term Healthcare Costs of Patients with Symptomatic Peripheral Artery Disease with and without a History of Atherosclerotic Disease: Results from a Swedish Nationwide Study , 2016 .

[18]  Deepak L. Bhatt,et al.  Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. , 2016, Journal of the American College of Cardiology.

[19]  Xinghuan Wang,et al.  Carbapenems vs alternative antibiotics for the treatment of complicated urinary tract infection , 2020, Medicine.

[20]  B. Modarai,et al.  Comparative Efficacy and Safety of Different Antiplatelet Agents for Prevention of Major Cardiovascular Events and Leg Amputations in Patients with Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis , 2015, PloS one.

[21]  Yongquan Gu,et al.  Prospective Randomized Study of Sarpogrelate Versus Clopidogrel-based Dual Antiplatelet Therapies in Patients Undergoing Femoropopliteal Arterial Endovascular Interventions: Preliminary Results , 2015, Chinese medical journal.

[22]  K. Urasawa,et al.  Cilostazol Reduces Angiographic Restenosis After Endovascular Therapy for Femoropopliteal Lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol Study , 2013, Circulation.

[23]  Wei Wang,et al.  Prospective study of sarpogrelate hydrochloride on patients with arteriosclerosis obliterans. , 2013, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.

[24]  D. Sobieraj,et al.  Dosing frequency and medication adherence in chronic disease. , 2012, Journal of managed care pharmacy : JMCP.

[25]  C. Claussen,et al.  Management of peripheral arterial interventions with mono or dual antiplatelet therapy—the MIRROR study: a randomised and double-blinded clinical trial , 2012, European Radiology.

[26]  Ying Su,et al.  Sarpogrelate inhibits the expression of ICAM-1 and monocyte–endothelial adhesion induced by high glucose in human endothelial cells , 2012, Molecular and Cellular Biochemistry.

[27]  E. Miyaoka,et al.  Comparisons of Test Statistics for Noninferiority Test for the Difference between Two Independent Binominal Proportions , 2010 .

[28]  M. Nobuyoshi,et al.  Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication. , 2009, Journal of the American College of Cardiology.

[29]  M. Kitakaze,et al.  Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. , 2008, Journal of vascular surgery.

[30]  S. Doggrell.  Sarpogrelate: cardiovascular and renal clinical potential , 2004, Expert opinion on investigational drugs.

[31]  M. Fujita,et al.  Sarpogrelate treatment reduces restenosis after coronary stenting. , 2003, American heart journal.

[32]  L. Sharma,et al.  Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. , 2001, JAMA.

[33]  J. Werner,et al.  Sarpogrelate inhibits serotonin-induced proliferation of porcine coronary artery smooth muscle cells: implications for long-term graft patency. , 2001, The Annals of thoracic surgery.

[34]  N. Sobol,et al.  PRELIMINARY RESULTS , 2004 .